Skip to main content

Advertisement

Table 3 Antimicrobial susceptibility of isolates of Enterobacter species and Escherichia coli

From: Erratum to: Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by Enterobacter species versus Escherichia coli: a matched case-control study

Antimicrobiala Enterobacter SBP
(n = 31)
E. coli SBP
(n = 125)
P
Cefotaxime 23/31 (74.2) 106/125 (84.8) 0.16
Ceftazidime 22/31 (71.0) 106/125 (84.8) 0.07
Ceftriaxone 22/31 (71.0) 106/125 (84.8) 0.07
Third-generation cephalosporinsb 22/31 (71.0) 106/125 (84.8) 0.07
Cefepime 25/29 (86.2) 103/123 (83.7) 1.00
Ciprofloxacin 25/31 (80.6) 76/125 (60.8) 0.038
Piperacillin/tazobactam 23/31 (74.2) 116/125 (92.8) 0.003
Imipenem 31/31 (100.0) 125/125 (100.0) 1.00
Trimethoprim-sulfamethoxazole 27/31 (87.1) 74/125 (59.2) 0.003
Amikacin 30/31 (96.8) 124/125 (99.2) 0.36
Gentamicin 27/31 (87.1) 84/125 (67.2) 0.03
Tobramycin 27/31 (87.1) 81/125 (64.8) 0.02
  1. Values are n (%) unless otherwise indicated
  2. aNot all of the isolates underwent susceptibility testing
  3. bMeans cefotaxime or ceftriaxone. The susceptibility to third-generation cephalosporins was defined by the breakpoints of the 2008 Clinical Laboratory Standards Institute guidelines (susceptible, ≤ 8 μg/ml; intermediate, 16–32 μg/ml; and resistant, ≥ 64 μg/ml) [18]